Clinical trials: Plasma Cell Leukemia
Cancer
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
This was a Phase II, open-label, non-randomized, multi-center study of oral dabrafenib in combination with oral trametinib in subjects with rare cancers harboring the BRAF V600E mutation including anaplastic thyroid cancer (ATC)…
- Trial name
- NCT02034110
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Austria and 12 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
The purpose of this study is to evaluate the multi-lineage hematopoietic chimerism for unrelated umbilical cord blood (UCB) grafts pooled from two to three cord blood units.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01500161
- Testing
- Busulfan, Clofarabine, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Texas Oncology Cancer Center
Lymphoma, Multiple Myeloma
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers: relapsed or refractory (R/R) lymphoma multiple myeloma newly diagnosed…
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03530683
- Testing
- Maplirpacept (PF-07901801), Azacitidine, Venetoclax
- Where
- 62 sites in United States
- Volunteers
- 189 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT02203825
- Testing
- CM-CS1 T-cell infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Celyad Oncology SA
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies.
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
- Trial name
- ADAPT-HEM (NCT07523555)
- Testing
- Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Beijing Biotech
Lymphoma, Non-Hodgkin, Lymphocytic Leukemia
Symbenda Post-Marketing Surveillance (PMS)
This is a PMS of Symbenda Injection (bendamustine hydrochloride) in Korean Patients. The main objective is to obtain safety information related to Symbenda treatment from clinical practice.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT02434484
- Where
- 9 sites in South Korea
- Volunteers
- 84 people
- Sponsor
- Eisai Korea Inc.
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)
Tumor Registry of Lymphatic Neoplasia
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
- Trial name
- TLN-Registry (NCT00889798)
- Volunteers
- 3,795 people
- Sponsor
- iOMEDICO AG
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
AML, ALL
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
This is a multicenter, open-label, dose escalation Phase 1 study.
- Conditions
- AML, ALL, Blast Crisis, MDS
- Trial name
- TG02-101 (NCT01204164)
- Testing
- TG02 citrate, Carfilzomib, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Neoplasms by Site, Lymphoma, Non-hodgkin
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer.
- Conditions
- Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT00562224
- Testing
- PCI-24781
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pharmacyclics LLC.
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or…
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT04977024
- Testing
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- GeoVax, Inc.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal…
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Trial name
- NCT04116437
- Testing
- Zanubrutinib
- Where
- 24 sites in United States
- Volunteers
- 96 people
- Sponsor
- BeiGene
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Mantle Zone Lymphoma Refractory/Recurrent
- Trial name
- NCT02981745
- Testing
- CT-1530
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Centaurus Biopharma Co., Ltd.
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers…
- Trial name
- THINK (NCT03018405)
- Testing
- NKR-2 cells
- Where
- 5 sites in United States, Belgium
- Volunteers
- 146 people
- Sponsor
- Celyad Oncology SA
Acute Leukemia, Chronic Leukemia
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma
- Trial name
- NCT00273936
- Testing
- AVN-944 capsules for oral administration
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Leukemia, Chronic Leukemia
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
Genzyme will evaluate/monitor the off label transplant use of plerixafor using data in the European Group for Blood and Marrow Transplantation (EBMT) registry.
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT01362985
- Volunteers
- 201 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse
- Trial name
- NCT01435720
- Testing
- SNS01-T
- Where
- 7 sites in United States, South Africa
- Volunteers
- 15 people
- Sponsor
- Senesco Technologies, Inc.
Plasma Cell Disorder
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.
- Trial name
- NCT05032339
- Testing
- IUO Plasma Cell Disorders Panel
- Where
- 5 sites in United States, Portugal and 3 more
- Volunteers
- 208 people
- Sponsor
- Becton, Dickinson and Company
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Multiple Myeloma, Myelodysplastic Syndromes
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02921802
- Where
- Japan
- Volunteers
- 4,626 people
- Sponsor
- Celgene